newsfilter
← Latest News
GlobeNewswire·

Gritstone bio and Genevant Sciences Announce Option and License Agreement

Agreement provides nonexclusive access to Genevant's leading LNP technology for use with Gritstone bio's self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year, multi-pathogen,